Life sciences team advises AstraZeneca on key transaction for vaccine for respiratory illnesses

01 September 2017
Client work

MEDI8897 is a monoclonal antibody that helps prevent lower respiratory tract illnesses caused by a virus that is the biggest cause of LRTI among infants and young children.

The agreement sees Sanofi Pasteur make an upfront payment of €120 million, plus a further payment of up to €495 million upon achievement of certain development and sales-related milestones. The companies will share all costs and profits equally and AstraZeneca will continue to lead all development activity.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences

Related Insights & Resources

View all insights Related Insights & Resources
Articles
09 April 2020 English Court of Appeal 'widens the target' for Arrow declarations (and hands control to defendants)
Articles
06 April 2020 Update from Singapore Courts and the Intellectual Property Office of Singapore in response to COVID-19
Articles
03 April 2020 New amendments affecting the pharmaceutical market in Russia – key points highlighted
Download or print PDF